SweetValueLab
Write for us

Danaher Corporation — Wall Street Analyst Estimates & Price Targets

DHR
NYSEHealthcareMedical - Diagnostics & ResearchCIK 0000313616danaher.comAbout DHR
Last close · Oct 16, 2026229.04−2.46 (−1.06%)
Market cap$161.0B

7 firms' latest targets, last 90 days: median $240.00 ($195.00–$250.00), 5% above the last close.

Price and published targets

daily close, 12 months · each dot a target, a firm's latest darker
$200$250NovJan 2026MarMayJulSep2025-10-22 · Baird: $2472025-10-23 · Wells Fargo: $2302025-12-01 · Morgan Stanley: $2702025-12-09 · Goldman Sachs: $2652025-12-15 · Wells Fargo: $2402026-01-05 · Evercore ISI: $2502026-01-14 · Argus Research: $2652026-01-28 · Jefferies: $2652026-01-28 · Evercore ISI: $2542026-01-29 · Baird: $2512026-04-14 · Barclays: $2302026-04-17 · Baird: $2492026-04-17 · Rothschild & Co Redburn: $2052026-04-21 · Jefferies: $2452026-05-14 · RBC Capital: $2002026-06-03 · HSBC: $2302026-06-11 · Piper Sandler: $2002026-07-06 · Evercore ISI: $2302026-07-22 · Deutsche Bank: $2402026-07-22 · RBC Capital: $2152026-07-22 · Stifel: $2202026-07-22 · Guggenheim: $2002026-07-22 · Wells Fargo: $1952026-09-09 · UBS: $2502026-10-01 · Guggenheim: $2502026-10-05 · RBC Capital: $2502026-10-12 · Morgan Stanley: $240
$200$250NovFebMayAug

Each firm's latest target

last 90 days · 7 firms
DateFirmTargetPreviousChangeVs price thenVs price now
2026-10-12Morgan Stanley$240.00$270.00▼ 11%+9%+5%
2026-10-05RBC Capital$250.00$215.00▲ 16%+17%+9%
2026-10-01Guggenheim$250.00$200.00▲ 25%+13%+9%
2026-09-09UBS$250.00——+22%+9%
2026-07-22Deutsche Bank$240.00——+37%+5%
2026-07-22Stifel$220.00——+23%-4%
2026-07-22Wells Fargo$195.00$240.00▼ 19%+9%-15%

Consensus estimates

revenue and EPS by fiscal year · reported years marked
FYRevenueYoYEPSYoYRevenue rangeEPS rangeAnalysts
2023reported$23.9B-24%$6.38-34%est. $27.1B-12%est. $7.4314
2024reported$23.9B+0%$5.29-17%est. $23.8B+0%est. $7.5011
2025reported$24.6B+3%$5.05-5%est. $24.5B+0%est. $7.7317
2026$26.4B+7%$8.50+10%$25.6B–$26.6B$8.45–$8.5217
2027$28.5B+8%$9.30+9%$27.2B–$29.2B$9.18–$9.4018
2028$30.3B+7%$10.23+10%$29.7B–$31.2B$9.11–$10.7516
2029$32.6B+7%$11.33+11%$31.8B–$33.1B$10.99–$11.5814
2030$33.9B+4%$12.48+10%$33.1B–$34.4B$12.11–$12.7614
A reported year shows the company's figures, with the consensus beside it (revenue against it in %). Reported EPS is GAAP diluted; the analysts' EPS usually leaves items such as stock compensation out, so the two are not like for like. Faded: a year the valuation models do not read — they read the first 3, and a later one only while 10 or more analysts cover every year up to it — or one under 5 analysts.

Targets, grades and estimates are quoted from third parties (via Financial Modeling Prep) and are theirs, not ours; each target links to the report it was published in. A firm counts once, at its latest target or grade.